Jefferies Group's CAPR Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 104,361 shares of Capricor Therapeutics, Inc. (CAPR) worth $3.17 M, representing 0.02% of the portfolio. First purchased in 2024-Q1, this short-term holding has been held for 3 quarters.
Based on 13F filings, Jefferies Group has maintained this position in CAPR for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2026, adding 104,361 shares. Largest reduction occurred in Q2 2024, reducing 10,600 shares.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's Capricor Therapeutics (CAPR) Holding Value Over Time
Track share changes against reported price movement
Quarterly Capricor Therapeutics (CAPR) Trades by Jefferies Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +104,361 | New Buy | 104,361 | $30.40 |
| Q2 2024 | -10,600 | Sold Out | 0 | $0.00 |
| Q1 2024 | +10,600 | New Buy | 10,600 | $6.79 |
Jefferies Group's Capricor Therapeutics Investment FAQs
Jefferies Group first purchased Capricor Therapeutics, Inc. (CAPR) in Q1 2024, acquiring 10,600 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held Capricor Therapeutics, Inc. (CAPR) for 3 quarters since Q1 2024.
Jefferies Group's largest addition to Capricor Therapeutics, Inc. (CAPR) was in Q1 2026, adding 104,361 shares worth $3.17 M.
According to the latest 13F filing for Q1 2026, Jefferies Group's firm, Jefferies Financial Group Inc., owns 104,361 shares of Capricor Therapeutics, Inc. (CAPR), valued at approximately $3.17 M.
As of the Q1 2026 filing, Capricor Therapeutics, Inc. (CAPR) represents approximately 0.02% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.
Jefferies Group's peak holding in Capricor Therapeutics, Inc. (CAPR) was 104,361 shares, as reported at the end of Q1 2026.